两种化疗方案辅助治疗乳腺浸润性导管癌的效果评价

Evaluation on the Effect of Adjuvant Treatment of Two Chemotherapy Regimens on Breast Infiltrating Ductal Carcinoma

目的:比较分析两种化疗方案辅助治疗乳腺浸润性导管癌的效果。方法:选取清远市妇幼保健院2018年7月至2020年6月收治的30例乳腺浸润性导管癌患者,并借助随机颜色球法将患者分为对照组和观察组,各15例,患者均为女性。对照组采用表柔比星+环磷酰胺联合多西他赛的化疗方案治疗,观察组则患者则采用多柔比星脂质体+环磷酰胺联合紫杉醇脂质体的治疗方案,对两组患者的临床治疗效果以及不良反应情况进行比较。结果:两组临床治疗效果接近,而在不良反应的比较上,观察组显著优于对照组,不良反应差异均存在统计学意义(P<0.05)。观察组患者的成本-效果更优。结论:对乳腺浸润性导管癌患者进行化疗的过程中,选用多柔比星脂质体+环磷酰胺联合紫杉醇脂质体,能够在保证治疗效果的同时,降低不良反应的发生率,并且,该种方法的成本-效果更优。

Objective To analyze the effect of adjuvant treatment of two chemotherapy regimens on breast infiltrating ductal carcinoma.Methods A total of 30 patients with invasive ductal carcinoma of breast admitted to Qingyuan Maternal and Child Health Care Hospital from July 2018 to June 2020 were selected and divided into control group and observation group with 15 cases in each group by random color ball method.All patients were female.The control group was treated with epirubicin plus cyclophosphamide combined with docetaxel,while the observation group was treated with doxirubicin liposome plus cyclophosphamide combined with paclitaxel liposome,and the clinical treatment effects and adverse reactions of the two groups were compared.Results The clinical treatment effect was similar between the two groups,and the observation group was significantly better than the control group in terms of adverse reactions,with statistical significance (P < 0.05).Conclusion The therapeutic regimen of doxirubicin liposome plus cyclophosphamide combined with paclitaxel liposome will not only guarantee the therapeutic effect but also reduce the incidence rate of adverse reactions in the chemotherapy process for patients with breast infiltrating ductal carcinoma.Moreover,this method has better cost and effect.